NuCana plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NCNA research report →
Price Chart
About the company
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer.
- CEO
- Hugh Stephen Griffith
- IPO
- 2017
- Employees
- 11
- HQ
- Edinburgh, MD, GB
Get TickerSpark's AI analysis on NCNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.62M
- P/E
- -6.95
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 4.29
- EV/EBITDA
- 0.95
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.95%
- ROIC
- -56.59%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-20,110,000
- Net Income
- $-29,353,000-54.5%
- EPS
- $-17.20+98.9%
- OCF Growth
- +60.9%
- FCF Growth
- +60.5%
- 52W High
- $7.22
- 52W Low
- $0.95
- 50D MA
- $1.38
- 200D MA
- $1.98
- Beta
- 2.31
- RSI (14)
- 35
- Avg Volume
- 124.69K
No earnings-call transcripts are available for NCNA yet.
- Free Float
- 94.1%
- Shares Outstanding
- 6.07M
- Float Shares
- 5.71M
of shares held by institutions
21 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Abingworth Llp | 3.33M | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 26 | Levy Elliott M. | sell | 23,811,896 |
| Jun 19, 26 | Bloss Jeffrey D. | sell | 36,539,720 |
| Apr 15, 26 | Bruce Theresa Margaret Ms | other | 132,600,130 |
| Mar 18, 26 | Levy Elliott M. | other | 0 |
| Mar 18, 26 | Levy Elliott M. | other | 3 |
| Mar 18, 26 | Levy Elliott M. | other | 28,631,517 |
| Mar 18, 26 | Harrison David James | other | 77,520,679 |
| Mar 18, 26 | Mellish Martin C.B. | other | 0 |
| Mar 18, 26 | Mellish Martin C.B. | other | 7 |
| Mar 18, 26 | Mellish Martin C.B. | other | 42,362,799 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NCNA coverage
Recent articles, reports, and earnings notes.
No research on NCNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NCNA report →NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
globenewswire.com · Sep 30
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 13
NuCana Appoints Ian Webster as Chief Financial Officer
globenewswire.com · Jun 1
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 14
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
globenewswire.com · Mar 19
NuCana Appoints Theresa Bruce as Chief Operating Officer
globenewswire.com · Jan 6
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
globenewswire.com · Dec 10
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.